Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.67 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.61 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.61 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.61 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | TNKS | O95271 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7490310 | 1.00 | OPRM1 (0.67) | OPRM1OPRL1OPRK1CHRM1CHRM2 | |
| SCHEMBL7489074 | 1.00 | OPRM1 (0.67) | OPRM1OPRL1OPRK1CHRM1CHRM2 | |
| SCHEMBL6214489 | 1.00 | OPRM1 (0.67) | OPRM1OPRL1OPRK1CHRM1CHRM2 | |
| SCHEMBL7542124 | 1.00 | OPRM1 (0.67) | OPRM1OPRL1OPRK1CHRM1CHRM2 | |
| SCHEMBL6834514 | 1.00 | OPRM1 (0.67) | OPRM1OPRL1OPRK1CHRM1CHRM2 | |
| SCHEMBL7486227 | 1.00 | OPRM1 (0.67) | OPRM1OPRL1OPRK1CHRM1CHRM2 | |
| SCHEMBL7492650 | 0.99 | OPRM1 (0.65) | OPRM1OPRL1OPRK1CHRM1CHRM2 | |
| SCHEMBL7547331 | 0.96 | OPRM1 (0.62) | OPRM1OPRL1OPRK1CHRM1CHRM2 | |
| SCHEMBL7492314 | 0.94 | OPRM1 (0.61) | OPRM1OPRL1OPRK1CHRM1CHRM2 | |
| SCHEMBL7497065 | 0.91 | OPRM1 (0.62) | OPRM1OPRL1OPRK1CHRM1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6423725-B1 | ANALGESICS | PFIZER INC | 2002-07-23 | — | — | US | claimed |
| EP-1049689-B1 | 4-(2-KETO-1-BENZIMIDAZOLINYL)PIPERIDINE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER (US) | 2002-06-26 | — | — | EP | claimed |
| EP-1049689-A1 | 4-(2-KETO-1-BENZIMIDAZOLINYL)PIPERIDINE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER INC. (US) | 2000-11-08 | — | — | EP | claimed |
| WO-1999036421-A1 | 4-(2-KETO-1-BENZIMIDAZOLINYL)PIPERIDINE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-07-22 | — | — | WO | claimed |
| US-20040067950-A1 | High affinity ligands for nociceptin receptor ORL-1 | SCHERING-PLOUGH CORPORATION | 2004-04-08 | — | — | US | disclosed |
| US-20030109549-A1 | 2-Substituted-1-piperidyl benzimidazole compounds as ORL1-receptor agonists | ITO FUMITAKA (JP) | 2003-06-12 | — | — | US | disclosed |
| EP-1102762-B1 | 2-SUBSTITUTED-1-PIPERIDYL BENZIMIDAZOLE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER (US) | 2002-11-13 | — | — | EP | disclosed |
| US-6423725-B1 | ANALGESICS | PFIZER INC | 2002-07-23 | — | — | US | disclosed |
| EP-1049689-B1 | 4-(2-KETO-1-BENZIMIDAZOLINYL)PIPERIDINE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER (US) | 2002-06-26 | — | — | EP | disclosed |
| EP-1102762-A2 | 2-SUBSTITUTED-1-PIPERIDYL BENZIMIDAZOLE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER INC. (US) | 2001-05-30 | — | — | EP | disclosed |
| US-6172067-B1 | ANALGESICS, ANTIINFLAMMATORY AGENTS | PFIZER INC. | 2001-01-09 | — | — | US | disclosed |
| EP-1049689-A1 | 4-(2-KETO-1-BENZIMIDAZOLINYL)PIPERIDINE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER INC. (US) | 2000-11-08 | — | — | EP | disclosed |
| WO-2000008013-A2 | 2-SUBSTITUTED-1-PIPERIDYL BENZIMIDAZOLE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 2000-02-17 | — | — | WO | disclosed |
| WO-1999036421-A1 | 4-(2-KETO-1-BENZIMIDAZOLINYL)PIPERIDINE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109549-A1 | 2-Substituted-1-piperidyl benzimidazole compounds as ORL1-receptor agonists | OPRL1, ORMDL3, OPRM1 | OPRM1 3/4885OPRL1 1/4885OPRK1 6/4885 |
| US-20040067950-A1 | High affinity ligands for nociceptin receptor ORL-1 | OPRL1, OPRD1, OGFRL1 | OPRM1 5/4885OPRL1 1/4885OPRK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.